Suppr超能文献

2019年慢性冠状病毒病化学感应功能障碍持续存在和恢复的决定因素。

Determinants of persistence and recovery of chronic coronavirus disease 2019 chemosensory dysfunction.

作者信息

Minichetti Dante G, Boyd Amelia, Lemire Evan, Hacker Jonathan, Haber Adam L, Roditi Rachel E, Albers Mark W, Lee Stella, Buchheit Kathleen M, Laidlaw Tanya M, Bankova Lora G

机构信息

Division of Allergy and Clinical Immunology, Jeff and Penny Vinik Center for Allergic Disease Research, Brigham and Women's Hospital and Department of Medicine, Harvard Medical School, Boston, Mass.

Department of Environmental Health, Harvard T. H. Chan School of Public Health, Boston, Mass.

出版信息

J Allergy Clin Immunol. 2025 Jan;155(1):120-134. doi: 10.1016/j.jaci.2024.08.027. Epub 2024 Sep 11.

Abstract

BACKGROUND

In 2% to 4% of patients, coronavirus disease 2019 (COVID-19) chemosensory dysfunction (CSD) persists beyond 6 months, accounting for up to 4 million people in the United States. The predictors of persistence and recovery require further exploration.

OBJECTIVE

We sought to define the predictors of recovery and assess the quality of CSD in registry subjects with self-reported persistent smell and taste dysfunction after COVID-19.

METHODS

COVID-19 CSD participants (n = 408) from the 4 major waves of the pandemic completed questionnaires at 4 time points between 2021 and 2023, assessing demographics, sinonasal symptoms, and self-assessed recovery. Objective measurements of smell (UPSIT) and taste (BWETT) were performed on a subcohort (n = 108).

RESULTS

In this chronic CSD cohort, the average symptom duration was 24 ± 5 months, with 70% of those who contracted COVID-19 in 2020 report ongoing dysfunction. Phantosmia and dysgeusia were most prevalent in the early waves of COVID-19, while most participants reported disrupted ability to distinguish scents and flavors as well as undulating chemosensory function. Subjects reported low incidence of subjective sinonasal symptoms but high prevalence of sleep and mood disturbance. Cigarette smoke phantosmia was predictive of persistence of CSD. Conversely, self-reported environmental allergies and hypertension were predictive of recovery, and dust mite allergies specifically were negative predictors of cigarette smoke phantosmia. Finally, no treatment resolved CSD, but nasal steroids were reported to be effective by recovered CSD subjects. Objective measures of both smell and taste were significantly reduced in patients with chronic CSD compared to controls.

CONCLUSIONS

Chronic COVID-19 CSD is a syndrome resistant to standard anti-inflammatory therapy. Preexisting environmental allergies and hypertension predict recovery, while cigarette smoke phantosmia predicts persistence.

摘要

背景

在2%至4%的患者中,2019冠状病毒病(COVID-19)的化学感觉功能障碍(CSD)会持续6个月以上,在美国多达400万人受此影响。持续存在和恢复的预测因素需要进一步探索。

目的

我们试图确定恢复的预测因素,并评估COVID-19后自我报告有持续嗅觉和味觉功能障碍的登记受试者的CSD质量。

方法

来自疫情4个主要阶段的COVID-19 CSD参与者(n = 408)在2021年至2023年期间的4个时间点完成了问卷调查,评估人口统计学、鼻窦症状和自我评估的恢复情况。对一个亚组(n = 108)进行了嗅觉(UPSIT)和味觉(BWETT)的客观测量。

结果

在这个慢性CSD队列中,平均症状持续时间为24±5个月,2020年感染COVID-19的患者中有70%报告仍有功能障碍。嗅觉幻觉和味觉障碍在COVID-19的早期阶段最为普遍,而大多数参与者报告区分气味和味道的能力受到干扰以及化学感觉功能波动。受试者报告主观鼻窦症状的发生率较低,但睡眠和情绪障碍的患病率较高。香烟烟雾幻觉是CSD持续存在的预测因素。相反,自我报告的环境过敏和高血压是恢复的预测因素,特别是尘螨过敏是香烟烟雾幻觉的负向预测因素。最后,没有治疗方法能解决CSD,但恢复的CSD受试者报告鼻用类固醇有效。与对照组相比,慢性CSD患者的嗅觉和味觉客观测量值均显著降低。

结论

慢性COVID-19 CSD是一种对标准抗炎治疗有抗性的综合征。既往存在的环境过敏和高血压预示着恢复,而香烟烟雾幻觉预示着持续存在。

相似文献

本文引用的文献

4
Smell and Taste Loss Associated with COVID-19 Infection.与 COVID-19 感染相关的嗅觉和味觉丧失。
Laryngoscope. 2023 Sep;133(9):2357-2361. doi: 10.1002/lary.30802. Epub 2023 Jun 2.
6
Phantom smells: a prevalent COVID-19 symptom that progressively sets in.幻嗅:一种普遍的 COVID-19 症状,且逐渐显现。
Eur Arch Otorhinolaryngol. 2023 Mar;280(3):1219-1229. doi: 10.1007/s00405-022-07649-4. Epub 2022 Sep 29.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验